



PRESS RELEASE

29.12.04

### **New EIA *Bordetella pertussis* detection from Ani Lab systems**

Ani Lab systems is now launching *Bordetella pertussis* assays, new generation specific EIAs for the detection of IgG-, IgA- and IgM-class antibodies against *B. pertussis* in human serum or plasma. These tests allow rapid testing, objective reading and parallel testing with *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* EIA assays of Ani Lab systems.

*B. pertussis*, *M. pneumoniae* and *C. pneumoniae* are all responsible for respiratory infections worldwide. Cases of these diseases may range from mild infections to life-threatening conditions. Due to wide variety of infections that can give rise to similar respiratory symptoms, clinical diagnosis of *B. pertussis*, *M. pneumoniae* and *C. pneumoniae* is essential.

Ani Lab systems have developed IgG, IgA and IgM EIA assays for *Bordetella pertussis*, *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* that can be run in parallel as they use similar format, procedure and the same pre-diluted sample. These Ani Lab systems' EIA detection kits come with ready to use reagents and can be easily adapted to automats.

The use of whole cell antigen in the Ani Lab systems' *B. pertussis* kits overcomes the pitfalls seen with the use of only one recombinant antigen.

Ani Lab systems has decades of experience in EIA assays. Ani Lab systems has always sought new challenges and solutions for clinical and research laboratories. In 1982, the company produced its first internationally recognised EIA kit for infectious diseases.